SAN MATEO, Calif., Nov. 3, 2016 /PRNewswire/ -- Lumiata, the AI-powered predictive analytics company, is pleased to announce the appointment of Chris Kryder, MD to its Board of Directors. Dr. Kryder, a leader in the healthcare information technology arena, has most recently served as Chairman of Valence Health, which merged with Evolent Health earlier this month. He was previously CEO of Verisk Health through its initial public offering following the merger of D2Hawkeye with ISO.
"Healthcare's shifting landscape demands highly precise, individualized and real-time analytics. Lumiata offers an exciting and meaningful solution that meets this demand," said Dr. Kryder. "Their medical AI technology is beginning to provide an end-to-end solution for risk bearers - from frictionless and fast data preparation, to precise, clinically-relevant risk analytics that can coordinate more targeted care interventions, and allocate resources to manage costs. I look forward to working with the Lumiata team and helping them accelerate deployment of their solution."
"We're very excited to add Chris to our board on the heels of our recent financing," said Ash Damle, founder and CEO of Lumiata. "Chris' deep understanding of how risk is managed, combined with his clinical background strengthens both the industry and subject matter expertise we have among our current directors, and brings tremendous value to Lumiata's medical AI offering. Moreover, Chris' willingness to join our board is a strong vote of confidence to our management and staff regarding the next-generation innovation we're bringing to the predictive analytics space."
Lumiata's technology, built by a core team of data scientists, clinicians and experts in care delivery, models human pathophysiology by mapping complex relationships between medical science, literature and patient data. The company's flagship product, the Lumiata Risk Matrix, applies dozens of predictive models to develop precise, holistic and clinically-relevant predictions of a patient's clinical conditions over time, which can then be applied toward multiple use cases in risk and care management. In addition, the Risk Matrix delivers evidentiary clinical reasoning behind every prediction, enabling better alignment, review and agreement between all stakeholders. Lumiata's technology is utilized by a number of leading organizations, including Universal American, Google, Intellivisit and a major BlueCross plan.
About Chris Kryder:
- Chairman Valence Health 2012-2016
- Founder of D2Hawkeye in 2001 and CEO of Verisk Health 2009-2011
- Co-founder of Generation Health - the first Genetics Testing Benefits Manager, sold in 2010 to CVS Caremark
- Internist and Clinical Operations Director, MIT Medical Department, Cambridge for 20 years
- Active faculty member of the Harvard Medical School for more than 25 years
- B.A. from the University of Buffalo, M.D from Georgetown University, MBA from the Massachusetts Institute of Technology; Internal Medicine Residency at Harvard.
Lumiata is a predictive analytics company that leverages medical artificial intelligence to enable health organizations to manage risk and prioritize care. The Lumiata Risk Matrix delivers precise, clinically-relevant predictions on individual risk over specific timeframes, with accompanying medical evidence. The company's core technological engine is the Lumiata Medical Graph, which analyzes hundreds of healthcare data sets within the context of clinical practice and the world's medical knowledge, and maps out insights on current and future health trajectories of individuals. Founded in 2013 and based in Silicon Valley, Lumiata's team is comprised of clinicians, data scientists, and experts in care delivery. For more information, visit www.lumiata.com or follow @lumiata.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/chris-kryder-joins-lumiata-board-of-directors-300356750.html